Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Time to treatment with intravenous alteplase and outcome in stroke : an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. / Lees, Kennedy R; Bluhmki, Erich; von Kummer, Rüdiger; Brott, Thomas G; Toni, Danilo; Grotta, James C; Albers, Gregory W; Kaste, Markku; Marler, John R; Hamilton, Scott A; Tilley, Barbara C; Davis, Stephen M; Donnan, Geoffrey A; Hacke, Werner; Allen, Kathryn; Mau, Jochen; Meier, Dieter; del Zoppo, Gregory; De Silva, D A; Butcher, K S; Parsons, M W; Barber, P A; Levi, C; Bladin, C; Byrnes, G; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group ; Iversen, Helle Klingenberg.

In: Lancet, Vol. 375, No. 9727, 15.05.2010, p. 1695-703.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Lees, KR, Bluhmki, E, von Kummer, R, Brott, TG, Toni, D, Grotta, JC, Albers, GW, Kaste, M, Marler, JR, Hamilton, SA, Tilley, BC, Davis, SM, Donnan, GA, Hacke, W, Allen, K, Mau, J, Meier, D, del Zoppo, G, De Silva, DA, Butcher, KS, Parsons, MW, Barber, PA, Levi, C, Bladin, C, Byrnes, G, ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group & Iversen, HK 2010, 'Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials', Lancet, vol. 375, no. 9727, pp. 1695-703. https://doi.org/10.1016/S0140-6736(10)60491-6

APA

Lees, K. R., Bluhmki, E., von Kummer, R., Brott, T. G., Toni, D., Grotta, J. C., Albers, G. W., Kaste, M., Marler, J. R., Hamilton, S. A., Tilley, B. C., Davis, S. M., Donnan, G. A., Hacke, W., Allen, K., Mau, J., Meier, D., del Zoppo, G., De Silva, D. A., ... Iversen, H. K. (2010). Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, 375(9727), 1695-703. https://doi.org/10.1016/S0140-6736(10)60491-6

Vancouver

Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010 May 15;375(9727):1695-703. https://doi.org/10.1016/S0140-6736(10)60491-6

Author

Lees, Kennedy R ; Bluhmki, Erich ; von Kummer, Rüdiger ; Brott, Thomas G ; Toni, Danilo ; Grotta, James C ; Albers, Gregory W ; Kaste, Markku ; Marler, John R ; Hamilton, Scott A ; Tilley, Barbara C ; Davis, Stephen M ; Donnan, Geoffrey A ; Hacke, Werner ; Allen, Kathryn ; Mau, Jochen ; Meier, Dieter ; del Zoppo, Gregory ; De Silva, D A ; Butcher, K S ; Parsons, M W ; Barber, P A ; Levi, C ; Bladin, C ; Byrnes, G ; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group ; Iversen, Helle Klingenberg. / Time to treatment with intravenous alteplase and outcome in stroke : an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. In: Lancet. 2010 ; Vol. 375, No. 9727. pp. 1695-703.

Bibtex

@article{5b02e453e5f045d28c3e024e2da9d22d,
title = "Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials",
abstract = "BACKGROUND: Early administration of intravenous recombinant tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome. Previous analysis of combined data from individual patients suggested potential benefit beyond 3 h from stroke onset. We re-examined the effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by adding recent trial data to the analysis.METHODS: We added data from ECASS III (821 patients) and EPITHET (100 patients) to a pool of common data elements from six other trials of alteplase for acute stroke (2775 patients). We used multivariate logistic regression to assess the relation of stroke onset to start of treatment (OTT) with treatment on favourable 3-month outcome (defined as modified Rankin score 0-1), mortality, and occurrence and outcome of clinically relevant parenchymal haemorrhage. The presence of an arterial occlusion was inferred from the patient's symptoms and absence of haemorrhage or other causes of ischaemic stroke. Vascular imaging was not a requirement in the trials. All patients with confirmed OTT within 360 min were included in the analysis.FINDINGS: Treatment was started within 360 min of stroke onset in 3670 patients randomly allocated to alteplase (n=1850) or to placebo (n=1820). Odds of a favourable 3-month outcome increased as OTT decreased (p=0.0269) and no benefit of alteplase treatment was seen after around 270 min. Adjusted odds of a favourable 3-month outcome were 2.55 (95% CI 1.44-4.52) for 0-90 min, 1.64 (1.12-2.40) for 91-180 min, 1.34 (1.06-1.68) for 181-270 min, and 1.22 (0.92-1.61) for 271-360 min in favour of the alteplase group. Large parenchymal haemorrhage was seen in 96 (5.2%) of 1850 patients assigned to alteplase and 18 (1.0%) of 1820 controls, with no clear relation to OTT (p=0.4140). Adjusted odds of mortality increased with OTT (p=0.0444) and were 0.78 (0.41-1.48) for 0-90 min, 1.13 (0.70-1.82) for 91-180 min, 1.22 (0.87-1.71) for 181-270 min, and 1.49 (1.00-2.21) for 271-360 min.INTERPRETATION: Patients with ischaemic stroke selected by clinical symptoms and CT benefit from intravenous alteplase when treated up to 4.5 h. To increase benefit to a maximum, every effort should be taken to shorten delay in initiation of treatment. Beyond 4.5 h, risk might outweigh benefit.FUNDING: None.",
keywords = "Fibrinolytic Agents, Humans, Infusions, Intravenous, Injections, Intravenous, Intracranial Hemorrhages, Randomized Controlled Trials as Topic, Recombinant Proteins, Stroke, Time Factors, Tissue Plasminogen Activator, Treatment Outcome",
author = "Lees, {Kennedy R} and Erich Bluhmki and {von Kummer}, R{\"u}diger and Brott, {Thomas G} and Danilo Toni and Grotta, {James C} and Albers, {Gregory W} and Markku Kaste and Marler, {John R} and Hamilton, {Scott A} and Tilley, {Barbara C} and Davis, {Stephen M} and Donnan, {Geoffrey A} and Werner Hacke and Kathryn Allen and Jochen Mau and Dieter Meier and {del Zoppo}, Gregory and {De Silva}, {D A} and Butcher, {K S} and Parsons, {M W} and Barber, {P A} and C Levi and C Bladin and G Byrnes and {ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group} and Iversen, {Helle Klingenberg}",
note = "Copyright 2010 Elsevier Ltd. All rights reserved.",
year = "2010",
month = may,
day = "15",
doi = "10.1016/S0140-6736(10)60491-6",
language = "English",
volume = "375",
pages = "1695--703",
journal = "Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "9727",

}

RIS

TY - JOUR

T1 - Time to treatment with intravenous alteplase and outcome in stroke

T2 - an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials

AU - Lees, Kennedy R

AU - Bluhmki, Erich

AU - von Kummer, Rüdiger

AU - Brott, Thomas G

AU - Toni, Danilo

AU - Grotta, James C

AU - Albers, Gregory W

AU - Kaste, Markku

AU - Marler, John R

AU - Hamilton, Scott A

AU - Tilley, Barbara C

AU - Davis, Stephen M

AU - Donnan, Geoffrey A

AU - Hacke, Werner

AU - Allen, Kathryn

AU - Mau, Jochen

AU - Meier, Dieter

AU - del Zoppo, Gregory

AU - De Silva, D A

AU - Butcher, K S

AU - Parsons, M W

AU - Barber, P A

AU - Levi, C

AU - Bladin, C

AU - Byrnes, G

AU - ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group

AU - Iversen, Helle Klingenberg

N1 - Copyright 2010 Elsevier Ltd. All rights reserved.

PY - 2010/5/15

Y1 - 2010/5/15

N2 - BACKGROUND: Early administration of intravenous recombinant tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome. Previous analysis of combined data from individual patients suggested potential benefit beyond 3 h from stroke onset. We re-examined the effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by adding recent trial data to the analysis.METHODS: We added data from ECASS III (821 patients) and EPITHET (100 patients) to a pool of common data elements from six other trials of alteplase for acute stroke (2775 patients). We used multivariate logistic regression to assess the relation of stroke onset to start of treatment (OTT) with treatment on favourable 3-month outcome (defined as modified Rankin score 0-1), mortality, and occurrence and outcome of clinically relevant parenchymal haemorrhage. The presence of an arterial occlusion was inferred from the patient's symptoms and absence of haemorrhage or other causes of ischaemic stroke. Vascular imaging was not a requirement in the trials. All patients with confirmed OTT within 360 min were included in the analysis.FINDINGS: Treatment was started within 360 min of stroke onset in 3670 patients randomly allocated to alteplase (n=1850) or to placebo (n=1820). Odds of a favourable 3-month outcome increased as OTT decreased (p=0.0269) and no benefit of alteplase treatment was seen after around 270 min. Adjusted odds of a favourable 3-month outcome were 2.55 (95% CI 1.44-4.52) for 0-90 min, 1.64 (1.12-2.40) for 91-180 min, 1.34 (1.06-1.68) for 181-270 min, and 1.22 (0.92-1.61) for 271-360 min in favour of the alteplase group. Large parenchymal haemorrhage was seen in 96 (5.2%) of 1850 patients assigned to alteplase and 18 (1.0%) of 1820 controls, with no clear relation to OTT (p=0.4140). Adjusted odds of mortality increased with OTT (p=0.0444) and were 0.78 (0.41-1.48) for 0-90 min, 1.13 (0.70-1.82) for 91-180 min, 1.22 (0.87-1.71) for 181-270 min, and 1.49 (1.00-2.21) for 271-360 min.INTERPRETATION: Patients with ischaemic stroke selected by clinical symptoms and CT benefit from intravenous alteplase when treated up to 4.5 h. To increase benefit to a maximum, every effort should be taken to shorten delay in initiation of treatment. Beyond 4.5 h, risk might outweigh benefit.FUNDING: None.

AB - BACKGROUND: Early administration of intravenous recombinant tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome. Previous analysis of combined data from individual patients suggested potential benefit beyond 3 h from stroke onset. We re-examined the effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by adding recent trial data to the analysis.METHODS: We added data from ECASS III (821 patients) and EPITHET (100 patients) to a pool of common data elements from six other trials of alteplase for acute stroke (2775 patients). We used multivariate logistic regression to assess the relation of stroke onset to start of treatment (OTT) with treatment on favourable 3-month outcome (defined as modified Rankin score 0-1), mortality, and occurrence and outcome of clinically relevant parenchymal haemorrhage. The presence of an arterial occlusion was inferred from the patient's symptoms and absence of haemorrhage or other causes of ischaemic stroke. Vascular imaging was not a requirement in the trials. All patients with confirmed OTT within 360 min were included in the analysis.FINDINGS: Treatment was started within 360 min of stroke onset in 3670 patients randomly allocated to alteplase (n=1850) or to placebo (n=1820). Odds of a favourable 3-month outcome increased as OTT decreased (p=0.0269) and no benefit of alteplase treatment was seen after around 270 min. Adjusted odds of a favourable 3-month outcome were 2.55 (95% CI 1.44-4.52) for 0-90 min, 1.64 (1.12-2.40) for 91-180 min, 1.34 (1.06-1.68) for 181-270 min, and 1.22 (0.92-1.61) for 271-360 min in favour of the alteplase group. Large parenchymal haemorrhage was seen in 96 (5.2%) of 1850 patients assigned to alteplase and 18 (1.0%) of 1820 controls, with no clear relation to OTT (p=0.4140). Adjusted odds of mortality increased with OTT (p=0.0444) and were 0.78 (0.41-1.48) for 0-90 min, 1.13 (0.70-1.82) for 91-180 min, 1.22 (0.87-1.71) for 181-270 min, and 1.49 (1.00-2.21) for 271-360 min.INTERPRETATION: Patients with ischaemic stroke selected by clinical symptoms and CT benefit from intravenous alteplase when treated up to 4.5 h. To increase benefit to a maximum, every effort should be taken to shorten delay in initiation of treatment. Beyond 4.5 h, risk might outweigh benefit.FUNDING: None.

KW - Fibrinolytic Agents

KW - Humans

KW - Infusions, Intravenous

KW - Injections, Intravenous

KW - Intracranial Hemorrhages

KW - Randomized Controlled Trials as Topic

KW - Recombinant Proteins

KW - Stroke

KW - Time Factors

KW - Tissue Plasminogen Activator

KW - Treatment Outcome

U2 - 10.1016/S0140-6736(10)60491-6

DO - 10.1016/S0140-6736(10)60491-6

M3 - Journal article

C2 - 20472172

VL - 375

SP - 1695

EP - 1703

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9727

ER -

ID: 128982899